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ABSTRACT
Objective: The capsaicin receptor TRPV1 (transient
receptor potential vanilloid type-1) may play an important
role in visceral pain and hypersensitivity states. In irritable
bowel syndrome (IBS), abdominal pain is a common and
distressing symptom where the pathophysiology is still
not clearly defined. TRPV1-immunoreactive nerve fibres
were investigated in colonic biopsies from patients with
IBS, and this was related to abdominal pain.
Methods: Rectosigmoid biopsies were collected from 23
IBS patients fulfilling Rome II criteria, and from 22
controls. Abdominal pain scores were recorded using a
validated questionnaire. TRPV1-, substance P- and
neuronal marker protein gene product (PGP) 9.5-expres-
sing nerve fibres, mast cells (c-kit) and lymphocytes (CD3
and CD4) were quantified, following immunohistochem-
istry with specific antibodies. The biopsy findings were
related to the abdominal pain scores.
Results: A significant 3.5-fold increase in median
numbers of TRPV1-immunoreactive fibres was found in
biopsies from IBS patients compared with controls
(p,0.0001). Substance P-immunoreactive fibres
(p=0.01), total nerve fibres (PGP9.5) (p=0.002), mast
cells (c-kit) (p=0.02) and lymphocytes (CD3) (p=0.03)
were also significantly increased in the IBS group. In
multivariate regression analysis, only TRPV1-immuno-
reactive fibres (p=0.005) and mast cells (p=0.008)
were significantly related to the abdominal pain score.
Conclusions: Increased TRPV1 nerve fibres are observed
in IBS, together with a low-grade inflammatory response.
The increased TRPV1 nerve fibres may contribute to
visceral hypersensitivity and pain in IBS, and provide a
novel therapeutic target.
Irritable bowel syndrome (IBS) is the most common
disorder presenting to gastroenterologists, with a
prevalence of up to 20% in the UK and the USA.
12
Patients commonly present with abdominal pain
associated with altered bowel habit. Self-reported
abdominal pain is a very common symptom in the
population including healthy individuals, but pain is
more severe and frequent in patients with IBS.
3
Untreated pain leads to a decrease in daily function
capability, social stresses, loss of work and poor
quality of life.
4 Furthermore, a study carried out by
Sandler et al
5 revealed that abdominal pain was the
symptom most likely to result in medical consulta-
tion in IBS patients. Therapeutic options currently
available are limited, and often disappointing in
efficacy. Functional bowel disorders such as IBS are
characterised by visceral hypersensitivity,
6 which
may manifest as pain associated with bowel
disturbances.
7 Although the pathogenesis of visceral
hypersensitivity is not fully understood, several
mechanisms have been proposed, including subtle
inflammation, psychosocial factors and altered
sensorimotor function of the gut, a major compo-
nent of which is believed to be peripheral and central
sensitisation of visceralafferent neuronal pathways.
8
The molecular and cellular mechanisms of the
pathophysiology of IBS are increasingly the subject
of study. The transient receptor potential vanilloid
type-1 (TRPV1 or VR1) has been shown to play a
role in animal models of inflammatory hyperalge-
sia. TRPV1 is expressed by sensory neurons and
activated by capsaicin,
9 heat (.43uC), acid
(pH,5.9) and inflammatory mediators, with
depolarisation leading to burning pain. TRPV1
activation also leads to local release of sensory
neuropeptides including calcitonin gene-related
peptide (CGRP) and substance P (SP) which, in
turn, activate their effector cell receptors and
contribute to the process of neurogenic inflamma-
tion. TRPV1 is expressed throughout the gastro-
intestinal (GI) tract in myenteric ganglia, muscular
layers and mucosa.
10 Our previous studies have
shown changes of TRPV1 in upper and lower GI
disorders: in inflammatory bowel disease, we
reported greatly increased TRPV1 immunoreactiv-
ity in biopsies taken from patients with active
painful Crohn’s disease compared with controls
(Yiangou et al
10). Our studies of biopsies from
patients with Hirschprung disease
11 and patients
with idiopathic rectal hypersensitivity with faecal
urgency
12 also revealed increased TRPV1-expressing
nerve fibres. In the latter study, increased levels of
TRPV1-expressing nerve fibres were correlated
significantly with hypersensitivity to rectal disten-
sion and mid-rectal heat stimulation (Chan et al
12).
Studies which specifically address any involve-
ment of TRPV1inIBSarelacking.Wehavetherefore
investigated the presence of TRPV1 nerve fibres in
colonic biopsies of IBS patients and controls, and
related these to the degree of abdominal pain. IBS
and control subjects were further characterised by
parameters known to be related to IBS such as the
neuropeptide SP, markers of inflammation including
c-kit (for mast cells) and psychological assessments
using validated questionnaires.
MATERIALS AND METHODS
Patients
The study was approved by Hammersmith
Hospitals Research Ethics Committee and all sub-
jects gave fully informed consent before taking part.
Twenty-three unselected patients with IBS and 22
controls participated in the study (see table 1). IBS
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or a colonoscopy (n=16) atHammersmith Hospital, London. IBS
was diagnosed according to the Rome II criteria and the subjects
were further subclassified according to Rome II criteria into either
diarrhoea-predominant (IBS-D), constipation-predominant (IBS-
C) or IBS with alternating stool pattern (IBS-A) (see table 2).
Controls were selected from patients who were undergoing
colonoscopy for other indications (such as polyp and cancer
surveillance) and had a normal colon (see table 3). None of the
patients was taking anti-inflammatory drugs or immunosuppres-
sants.IBS patients had previously beenseeninclinic, and other GI
diseaseshad beenexcluded.Coeliacdisease wasexcludedinall IBS
patients by checking coeliac serology (immunoglobulin A (IgA),
antiendomysial and antitissue transglutaminase (TTG) antibo-
dies). Patients under active psychiatric care were excluded.
Patients who were undergoing colonoscopy received standard
bowel preparation in the form of 4 litres of Kleanprep. For
flexible sigmoidoscopy patients received a phosphate enema 1 h
prior to the procedure. All patients had macroscopically normal
bowel mucosa on examination. A total of four mucosal biopsy
specimens were taken using standard biopsy forceps from all
subjects from the rectosigmoid junction in order to standardise
the site of sampling. Of these, two biopsies were sent for
routine H&E histological analysis to exclude any evidence of
inflammation and two for immunohistochemical staining using
specific antibodies.
Questionnaires
Pain severity, depression and anxiety
Patients and controls were given a pain diary to complete for the
7 days prior to commencing their bowel preparation for
endoscopy. The validated Short Form McGill Pain
Questionnaire (SF-MPQ) was used.
13 This has a 0–10 cm visual
analogue scale for patients to record pain severity or ‘‘present
pain intensity-visual analogue scale’’ (PPI-VAS), and a descrip-
tive table to characterise the type of pain and formulate a
sensory and affective pain score. The pain scores from these
diaries were collected and the maximum recorded PPI-VAS over
the 7 days, or VASmax, noted for each subject. As typically IBS
patients experience episodic pain which lasts 1–2 days, the
VASmax was thought to be more representative of the impact
of pain on the IBS patients than the mean pain score. The mean
pain score, or VASav, was also calculated.
Depression was measured using the Beck Depression
Inventory (BDI).
14 This consists of a 21-item measure with a
4-point intensity scale widely used as a self-report measure that
evaluates the presence and severity of depressive symptoms.
Participants were asked to complete the BDI based on how they
had been feeling over the past 2 weeks. A score of .13 indicates
a degree of depression.
The Hospital Anxiety and Depression Scale (HADS),
15 which
is a 14-item self-report questionnaire with a 4-point intensity
scale for each item to measure anxiety and depression severity in
a medical context, was given to each subject to complete. This
has two subscales (anxiety and depression) with each subscale
giving maximum scores of 21, and total scores range from 0 to
42. A score of 8 or above on a subscale signifies a degree of
anxiety/depression.
Patients were asked to complete the questionnaires at home
so they had time to comprehend and complete them and then
return them via the post.
Immunohistochemistry and histology
The two rectosigmoid biopsies were fixed in buffered 10%
formalin and processed routinely for H&E histology. The
histological sections were all evaluated by an experienced GI
pathologist.
A further two biopsies were used for immunohistochemistry
using c-kit/CD117, CD3 and CD4 antibodies to exclude
inflammation or other pathology, and antibodies for TRPV1,
SP and the pan-neuronal structural nerve marker protein gene
product (PGP) 9.5. The primary antibodies used in the study are
listed in table 4, and they were used as described previously.
12
Tissues were snap-frozen and stored at 270uC or immersed in
fixative (4% (w/v) paraformaldehyde in phosphate-buffered
saline (PBS: 0.1 M phosphate; 0.9% (w/v) saline; pH 7.3)) then
washed in PBS containing 15% (w/v) sucrose and 0.05% (w/v)
azide for 1 h before snap freezing in embedding medium
(Tissue-Tek OCT compound, Sakura Finetek, Torrance,
California, USA). Frozen tissue sections (15 mm) were collected
onto poly-L-lysine-coated (Sigma, Poole, Dorset, UK) glass
slides. Unfixed tissue sections were postfixed in 4% (w/v)
paraformaldehyde, whilst tissue sections from immersion fixed
biopsies were allowed to dry on the slide (for SP and PGP9.5
antibodies only). Endogenous peroxidase was blocked by
incubation in 0.3% (w/v) hydrogen peroxide in industrial
methylated spirit. After rehydration in PBS, sections were
incubated overnight with primary antibodies (table 4). Controls
included omission of primary antibodies, or their replacement
with preimmune serum. The specificity of TRPV1 immunos-
taining was confirmed by preincubation of primary antibodies
with cognate peptide antigen as previously described by us in
human intestine.
12 Sites of antibody attachment were revealed
using the nickel-enhanced, immunoperoxidase method (avidin–
biotin complex, ABC elite; Vector Laboratories, High Wycombe,
Bucks, UK). Nuclei were counterstained with 0.1% (w/v)
aqueous neutral red.
Analysis of immunoreactive fibres
Immunoreactive nerve fibres and cell markers were quantified
by computerised image analysis (Olympus Analysis Five DP
Soft, UK). Analogue images were captured via video link to an
Olympus BX50 microscope and converted into digital mono-
chrome images by the computer. The grey-shade detection
threshold was set at a constant level to allow detection of
positive immunostaining, and the area of highlighted immunor-
eactivity in the mucosa was obtained as a percentage (% area) of
the field scanned. Five fields (640 objective magnification) per
tissue section, chosen at random, were scanned, and the mean
values of readings obtained by two independent blinded
observers were used for final analysis. For TRPV1 analysis, as
the immunostaining revealed fine fibres, the total numbers of
fibres were counted per section and results were expressed as
Table 1 Patient demographics
Number Age (years) Gender (M:F)
Control 22 64 (55–75) 7:15
IBS 23 53 (30–65) 3:20
IBS-D 8 34 (26–57) 1:7
IBS-C 8 59 (49–69) 2:6
IBS-A 7 65 (24–70) 0:7
Values are the median and interquartile range.
F, female; IBS, irritable bowel syndrome; IBS-A, IBS with an alternating stool pattern;
IBS-C constipation-predominant IBS; IBS-D diarrhoea-predominant IBS; M, male.
Neurogastroenterology
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2. Further details of methods are
provided in our previous paper (Chan et al).
12
Statistical analysis
Data were compared using the Mann–Whitney U test with
Winstat for EXCEL software. p Values ,0.05 were considered as
statistically significant. Correlations between two parameters
were performed using Spearman rank correlation. Univariate
and multivariate linear regression models were used to assess
the associations between primary antibody variables and
VASmax. All data are reported as median values and inter-
quartile range unless otherwise stated.
RESULTS
All biopsies were reported as normal for H&E histology.
Neuronal markers
TRPV1-immunoreactive fine fibres were seen scattered through-
out the mucosa in all biopsies, but were more abundant in those
from IBS patients than controls (fig 1A,B). Quantitation
revealed that the median number of TRPV1 fibres was
significantly (3.5-fold) higher in IBS patients compared with
controls (p,0.0001, table 5). SP-immunoreactive fibres
(fig 1C,D) were also significantly (3-fold) greater in IBS patients
compared with controls (p=0.01, table 5), as were PGP9.5-
immunoreactive fibres (p=0.002, fig 1E,F, table 5).
When the IBS group was divided into symptom subgroups,
there was no statistically significant difference in the numbers
of TRPV1-immunoreactive fibres (IBS-D, n=8, fibres/mm
2,
median 3.7, interquartile range 2.6–6.6; IBS-C, n=7, 3.5, 2.1–4.9;
and IBS-A, n=8, 2.2, 2.0–5.2; ANOVA (analysis of variance)
test, p=0.23).
In order to exclude possible changes arising from differences
in bowel preparation, the IBS group was also analysed by
whether they had a flexible sigmoidoscopy (n=7) or a
colonoscopy (n=16). TRPV1-immunoreactive fibres in the
flexible sigmoidoscopy group (3.2; 2.1–4.5) and in the colono-
scopy group (3.4; 2.2–5.6) were not significantly different
(p=0.6). Similarly PGP9.5-staining fibres (flexible sigmoido-
scopy 5.0; 3.7–5.5 vs colonoscopy 5.0; 3.1–7.2; p=0.8) and SP-
staining fibres (flexible sigmoidoscopy 2.4; 1.2–2.8 vs colono-
scopy 1.6; 0.7–3.4; p=0.6) did not differ significantly between
the two groups.
As there was a difference in the age structure of the IBS and
control groups, we also compared TRPV1 results in a subgroup
of 13 subjects from the IBS and 13 subjects from the control
group, both with an age range 50–75 years. In these age-
matched subgroups, TRPV1-immunoreactive fibres were sig-
nificantly increased in the IBS group (3.0; 2.2–4.8) compared
with the control group (1.0; 0.6–2.1; p=0.003). Multivariate
linear regression analysis revealed that, unlike the presence of
IBS, gender, age and type of bowel preparation/procedure were
not significant independent predictors of TRPV1 levels (fig 2).
Inflammatory markers
CD3+ T cells were seen scattered throughout the mucosa in all
the specimens (fig 3A,B), including controls. There was a
significantly greater percentage area of CD3+ cells in the IBS
group compared with the controls (p=0.03, table 4). Similar
staining but of fewer cells was seen using the CD4 T cell
antibody in both groups, and this was not statistically
significant (p=0.29, table 4). Mast cells immunoreactive to c-
kit were also scattered throughout the mucosa (fig 3C,D), and
were significantly elevated in the IBS group compared with
controls (p=0.02, table 4). With subgroup analysis of the
flexible sigmoidoscopy versus colonoscopy group to exclude
possible effects of differing bowel preparation, c-kit staining
(flexible sigmoidoscopy 5.5; 3.4–6 vs colonoscopy 3.9; 2.6–4.5)
did not differ significantly (p=0.2) between the two groups.
Pain severity, depression and anxiety
As expected, the median VASmax pain score was significantly
higher in IBS patients than in controls (IBS 4.5; 1.4–6.5 vs
control 0; 0–1.25; p=0.002). Univariate linear regression
Table 2 Symptoms reported by patients with irritable bowel syndrome
IBS-type Stool frequency
Stool consistency/
type (Bristol stool
form scale)
Frequency of abdominal
pain in days/week
IBS-D 3–4/day 7 7
IBS-A Variable 2, 3, 7 7
IBS-C Once every 2–3 days 2, 3 6
IBS-A Variable 3, 6 2
IBS-A Variable 3, 6 7
IBS-A Variable 2, 3, 6 7
IBS-D 2–3/day 7 7
IBS-C Once every 1–2 days 3 2
IBS-C Once every 2 days 2 1
IBS-D 3–4/day 6, 7 7
IBS-A Variable 2, 6 2
IBS-C Once every 1–2 days 2 0 (pain every few weeks)
IBS-D 3/day 7 6
IBS-D 2/day 6 3
IBS-C Once every 2 days 2 3
IBS-C Once every 1–2 days 2 1
IBS-D 4–5/day 7 7
IBS-A Variable 2, 6 7
IBS-D 4/day 6 2
IBS-A Variable 2, 7 5
IBS-A Variable 3, 6 2
IBS-C Once every 1–3 days 2 3
IBS-D 4/day 6 2
IBS-A, irritable bowel syndrome with an alternating stool pattern; IBS-C constipation-
predominant irritable bowel syndrome; IBS-D diarrhoea-predominant irritable bowel
syndrome.
Table 3 Indications for colonoscopy in the control group
Indication for colonoscopy n
Polyp follow-up 8
Polyp follow-up; family history of colorectal cancer 1
Iron deficiency 4
Per rectal bleeding 7
Family history of colorectal cancer 2
Table 4 Primary antibodies
Antibody Host Source: Reference Titre
TRPV1 Rabbit GSK/C22 1:10 000
Substance P Rabbit Chemicon UK 1:8000
PGP9.5 Rabbit Ultraclone 1/80 000
CD3 Mouse Dako Cytomation, Ely, UK Clone UCHTI 1:5000
CD4 Mouse Dako Cytomation, Ely, UK Clone MT310 1:5000
c-kit Mouse Novacastra, Newcastle upon Tyne, UK,
clone 57A5D8
1:2000
PGP, protein gene product; TRPV1, transient receptor potential vanilloid type-1.
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only TRPV1 (p=0.005, r=0.43), c-kit (p=0.004, r=0.47) and
age (p=0.02; r=20.34) data were statistically significantly
related to the pain score VASmax. These three variables were
introduced into a stepwise multivariate linear regression model
which revealed that only TRPV1 (p=0.005) and c-kit
(p=0.008) were significant predictors of VASmax.
The average VAS pain score was significantly greater in the
IBS group; median IBS group 1.7; 0.6–4.1 vs control 0; 0–0.5
(p=0.001). The average pain score also significantly correlated
with TRPV1 in the IBS group (p=0.02, r=0.5, Spearman
correlation) but not in the control group (p=0.5; r=20.02,
Spearman correlation). If the single outlier in the IBS group
with the high pain score is excluded and the data re-analysed to
ensure that this point does not skew the p value, then there was
still a positive correlation within the IBS group of pain scores
with TRPV1 levels (Spearman correlation r=0.4; p,0.05).
When the two groups were combined together, the average pain
score (VASav) also correlated with TRPV1 levels (p,0.001,
r=0.5 Spearman correlation) (see fig 4A–C). There was no
correlation seen with pain score and CD3 or mast cell counts.
The age range of the IBS patients varied from 21 to 77 years,
with six patients aged (30 years. If these six patients aged (30
years are selected as a subgroup, then there is still a positive
correlation between TRPV1 expression and VASav (Spearman
correlation r=0.7, p=0.04).
The HADS total scores in the IBS group (median 11.5, range
0–17) and control groups (median 9.5, range 2–25) were not
statistically different (p.0.05). Anxiety subscale scores (IBS
group median 7.5 vs control group median 6.5) and depression
subscale scores (IBS group median 5 vs control group median 4)
were also similar in the two groups. Similarly, BDI scores in the
IBS group (median 9, range 1–24) did not significantly differ
(p.0.05) from the control group (median 10.5, range 1–19).
DISCUSSION
The demonstration of increased mucosal nerve fibres immunor-
eactive to TRPV1 in human colonic biopsies from IBS patients,
and their correlation with the degree of abdominal pain, may
provide a putative basis of IBS symptoms. The increased TRPV1
nerve fibres were seen throughout the IBS group, with no
difference when the group was subclassified by Rome II
definitions into IBS-D, IBS-C and IBS-A.
Winston et al
16 have presented animal data which strengthen
the role of TRPV1 in visceral hypersensitivity. Acetic acid
colonic irrigation was used to induce a state of chronic visceral
Figure 1 Photomicrographs showing transient receptor potential vanilloid type-1 (TRPV1)- (arrowed), substance P and protein gene product (PGP)
9.5-immunoreactive fibre immunostaining in a control (A, C and E) and an irritable bowel syndrome rectosigmoid biopsy (B, D and F), magnification640.
Table 5 Quantitation of immunoreactivities in colonic biopsies from IBS and controls
n TRPV1 SP PGP9.5 c-kit CD3 CD4
IBS 23 3.2 (2.2–5.1) 2.3 (0.7–3.1) 5.0 (3.2–6.1) 4.0 (2.9–5.6) 8.7 (5.9–12.1) 1.0 (0.5–3.8)
Control 22 0.9 (0.5–2.1) 0.8 (0.5–1.5) 2.7 (1.7–3.8) 2.9 (1.9–3.9) 5.4 (3.9–7.9) 1.0 (0.3–1.8)
Ratio of medians
IBS:control
– 3.56 2.96 1.86 1.36 1.60 0.98
p Value – ,0.0001 0.01 0.002 0.02 0.03 0.29
Values are medians with interquartile range in parentheses. TRPV1 is expressed as fibres/mm
2, and the other immunoreactivities as
percentage area. Significance of differences between IBS and controls was determined by Mann–Whitney U test.
IBS, irritable bowel syndrome; PGP, protein gene product; SP, substance P; TRPV1, transient receptor potential vanilloid type-1.
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TRPV1 expression in dorsal root ganglia containing colonic
afferent neurons. Treatment with a TRPV1 antagonist amelio-
rated sensitivity, when used both in the neonates prior to the
acetic acid colonic irrigation, and in the adult hypersensitive
rats. Their work suggests that TRPV1 is probably important
both in initiating the process of visceral hypersensitivity and in
maintaining it. In agreement with this, we have reported
increased levels of TRPV1 in patients with idiopathic rectal
hypersensitivity and faecal urgency: in this group of patients,
the increased TRPV1 nerve fibres were correlated with rectal
distension and heat thresholds (Chan et al
12).
Our biopsies were obtained from IBS patients who were
having either a colonoscopy or a flexible sigmoidoscopy. All
control patients had a colonoscopy. We use different methods of
bowel preparation in these two procedures; a phosphate enema
for flexible sigmoidoscopy and Kleanprep for colonoscopy.
There have been reports that bowel preparations may be
responsible for histological changes
17 with both enemas
18 and
colonoscopy sodium phosphate-containing bowel prepara-
tions.
19 20 However, despite the use of these two different
preparations, all biopsies were reported histologically as normal
so there were no apparent changes induced due the type of
preparation used. Furthermore, the changes seen with immu-
nohistochemical markers for immune cells were similar through
the IBS group. Only seven of the 23 IBS patients underwent a
flexible sigmoidoscopy, so the majority had a full colonoscopy
with identical bowel preparation to the controls. There were no
statistically significant differences in any staining markers
between the patients who underwent a flexible sigmoidoscopy
and those who had a colonoscopy in the IBS group.
Although our two groups differed slightly in age, multivariate
regression analysis showed that this did not affect the results.
Our IBS group had an age and sex spread similar to the IBS
group published recently by Barbara et al
21 investigating mast
cell mediators in IBS. Furthermore, an age-matched subgroup
analysis revealed that the TRPV1-immunoreactive nerve fibres
were still significantly increased in the IBS group. The number
of IBS patients and controls in the overall group and in this
subgroup were powered at the 80% level to detect differences in
TRPV1 fibre number of 0.5 and 1.5 fibres/mm
2 at p,0.05.
Although both control and IBS biopsies were categorised as
normal on standard histology and mucosal endoscopic views
were normal, the CD3 count and c-kit expression were both
significantly higher in the IBS group. Our findings are consistent
with results from previous studies.
22–24 These have reported
increased mast cell numbers in colonic biopsies,
22 23 25 as we have
noted. Barbara et al found that mast cells which were proximal
to nerves correlated with abdominal pain severity, suggesting a
role for mast cells and their mediators in the altered
sensorimotor pathophysiology of IBS.
22 26 Our results also
showed that mast cell numbers/c-kit staining (but not mast
cell tryptase staining—data not shown) correlated positively
Figure 2 Transient receptor potential vanilloid type-1 (TRPV1) levels for
the irritable bowel syndrome (IBS) and control groups; p,0.001.
Figure 3 Photomicrographs showing
CD3- and c-kit-immunoreactive staining
cells in a control (A and C, respectively)
and an irritable bowel syndrome
rectosigmoid biopsy (B and D,
respectively). Magnification 640.
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27 took biopsies from
patients with IBS from different ileocolonic sites during
colonoscopy and, using immunohistochemistry techniques,
demonstrated an increase in mast cell numbers and SP-staining
immunoreactive fibers, and also a spatial correlation between
the two. Increased T lymphocytes have been reported in both
infectious and non-postinfectious IBS.
28–30 These results impli-
cate that a low-grade inflammatory process in IBS could be
involved in the pathogenesis of IBS, and that mast cell
interaction with nerve fibres including SP-positive fibres may
be important, in accord with our findings. From 6% to 17% of
unselected IBS patients cite an infectious trigger for their onset
of IBS symptoms, and prospective studies suggest an incidence
of postinfectious IBS which follows a bacterial gastroenteritis of
4–31%.
31 Other inflammatory cells have also been linked to
postinfectious IBS; Dunlop et al reported 20% increased
numbers of enterochromaffin (EC) cells
30 which contain
serotonin 3 months after the initial infective gastroenteritis
when compared with controls. When EC cells are triggered, they
release serotonin which acts on nearby receptors and nerve
endings. Furthermore there have been reports of increased
cytokines in peripheral blood of IBS patients.
32 33 These findings
strengthen the role of an inflammatory process in triggering IBS.
Although there is increasing evidence that sensorimotor
dysfunction in IBS is likely to result from an interaction
between mucosal immune cell mediators, nerve fibres and
muscle layers, further studies into the triggering and predispos-
ing mechanisms are needed. Various factors proposed include
infective gastroenteritis, genetic causes, food allergies and
alterations in gut microflora.
34 Interestingly, TRPV1 expression
has been reported on mast cells.
35 Stander et al
35 reported VR1
expression on dermal mast cells, suggesting a role in activation
of these cells and perpetuation of inflammation.
TRPV1 is likely to be activated by the products of
inflammation in IBS, and, through its upregulation, may
contribute to symptoms including pain. There was evidence
of nerve fibre sprouting in IBS, as PGP9.5 nerve fibres were
increased. Inflammation-mediated upregulation of TRPV1 is
well established, and has been shown to involve various
mechanisms including nerve growth factor (NGF) and
p38MAP kinase, along with sensitisation of TRPV1 by
bradykinin B2 via intracellular enzymatic pathways. NGF
production in peripheral tissues is enhanced by inflammation,
and NGF is taken up and transported in a retrograde manner by
nerve fibres to their cell bodies, leading to nerve sprouting and
increased expression of TRPV1 and SP.
36 Not only does NGF
sensitise TRPV1 receptors to protons, enhancing their effect,
but it also increases expression of TRPV1. Increased NGF, and
recently trk A, expression has been reported in acute inflam-
matory bowel disease.
37 38 Ji et al
38 have shown that the increase
in TRPV1 levels which occurs 12–24 h after inflammation is by
an NGF-mediated p38 kinase pathway. TRPV1 activity is
modulated by inflammatory mediators including bradykinin
and prostaglandins, probably by cAMP-dependent protein
kinase (PKA)- or protein kinase C (PKC)-mediated phosphoryla-
tion of the receptor.
39 Generally, protein kinase-mediated
phoshorylation of the TRPV1 receptor results in sensitisation,
and dephosphorylation by protein phosphatases results in
desensitisation.
40 NGF immunostaining has been difficult to
obtain in gut specimens, especially mucosal biopsies as we have
used here. Future studies would be useful to assay NGF, with
different processing of tissues.
Our findings, of increased total nerve fibres, and nerve fibres
immunoreactive to TRPV1 and SP in IBS, may thus all be
mediated via the effects of NGF. There are other mechanisms,
however, that may also modulate TRPV1 function—Sugiura et
al
41 reported data from a mouse model suggesting that 5-
hydroxytryptamine (5-HT, serotonin) receptor activation may
enhance the responsiveness of the TRPV1 receptor to acid and
temperature, and thereby contribute to peripheral sensitisation.
It is thought that this response is mediated via 5-HT2 or 5-HT4
receptors. Serotonin signalling alterations seen in IBS may act in
part via TRPV1 sensitisation.
TRPV1 activation produces an influx of calcium and sodium
ions, along with release of neuropeptides (SP, CGRP). This in
turn triggers and promotes the process of neurogenic inflamma-
tion. The oral TRPV1 antagonist JNJ 10185734 has been
reported to attenuate dextran sulfate sodium (DSS)-induced
colitis in mice, suggesting a possible role for TRPV1 in initiation
or maintenance of inflammation in the gut.
42 Other previous
Figure 4 (A) Scatter plot to show the correlation between transient
receptor potential vanilloid type-1 (TRPV1) levels and average pain
scores (VASav) in irritable bowel syndrome (IBS) subjects. Pearson
correlation r=0.68, p,0.001. Spearman correlation r=0.45, p=0.02.
(B) Scatter plot to show the correlation between TRPV1 levels and
average pain scores (VASav) in control subjects. Pearson correlation
r=20.1, p=0.34. (C) Scatter plot to show the correlation between
TRPV1 levels and VASav in all subjects (controls and IBS). Pearson
correlation r=0.6, p,0.001. Spearman correlation r=0.46; p,0.001.
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inflammation and hyperalgesia. In a rat model of DSS colitis,
43
neonatal animals chemically denervated of TRPV1 fibres by
treatment with capsaicin, and those given a TRPV1 antagonist
in established DSS colitis, were both protected from the
damaging effects of DSS.
Co-localisation studies would give further information as to
the origin of the nerve fibres under study, subject to the
availability of good antibodies for TRPV1 and SP raised in
different species. Such studies may also provide insight into the
relationship of these markers to abdominal pain score. The two
primary antibodies used in this study are both anti-rabbit
(table 4), thereby precluding co-localisation by immunohisto-
chemistry.
There have been reports of a higher incidence of anxiety and
depressive symptoms in IBS patients than in controls,
44 45 but
our IBS patients had similar BDI and HADS scores to those of
the control group. Central factors are likely to play an
important role in the generation of pain and visceral hypersen-
sitivity as well as peripheral mechanisms.
34 In this study we
focused on the peripheral sensitising mechanisms involving low-
grade inflammation and neuronal interactions in the generation
of pain.
In summary, we present evidence that TRPV1 nerve fibres are
increased in the mucosa of IBS patients. Our results provide a
mechanism which may contribute to the pathophysiology of
pain in IBS, and clinical trials with TRPV1 antagonists are
warranted in this condition.
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